Junshi licenses COVID-19 antibody tech from Lonza
14-07-2020
Danish biotech company secures CRISPR licence
04-06-2019
Charpentier granted new CRISPR/Cas9 patent
23-04-2019
Locus licenses CRISPR tech to Janssen in potential $818m deal
09-01-2019
ralwel / iStockphoto.com
ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
CRISPR/cas9, Eric Rhodes, Syngulon, patent dispute, University of California, University of Vienna, Emmanuelle Charpentier
